VYGR Logo

Voyager Therapeutics, Inc. (VYGR) 

NASDAQ
Market Cap
$230.52M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
928 of 937
Rank in Industry
529 of 534

Largest Insider Buys in Sector

VYGR Insider Trading Activity

VYGR Median Price and Trade Amounts History Chart

About Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear …

Insider Activity of Voyager Therapeutics, Inc.

Over the last 12 months, insiders at Voyager Therapeutics, Inc. have bought $0 and sold $374,797 worth of Voyager Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Voyager Therapeutics, Inc. have bought $20.58M and sold $3.79M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 4,395,588 shares for transaction amount of $39.03M was made by NEUROCRINE BIOSCIENCES INC (10 percent owner) on 2023‑02‑23.

List of Insider Buy and Sell Transactions, Voyager Therapeutics, Inc.

2025-02-11SalePresident & CEO
16,644
0.0255%
$4.45$74,066+3.44%
2025-02-11SaleCOO & CBO
6,950
0.0106%
$4.45$30,928+3.44%
2025-02-11SaleChief Legal Officer
4,358
0.0067%
$4.45$19,393+3.44%
2025-02-11SaleChief Scientific Officer
5,413
0.0083%
$4.45$24,088+3.44%
2025-01-14SaleCOO & CBO
3,087
0.0057%
$5.09$15,713+5.45%
2025-01-14SaleChief Scientific Officer
1,191
0.0022%
$5.13$6,110+5.45%
2024-12-23SaleCOO&CBO
6,500
0.0117%
$5.65$36,725-4.89%
2024-10-02SaleChief Legal Officer
5,999
0.0109%
$5.82$34,914+1.63%
2024-04-02SalePresident and CEO
12,115
0.0222%
$9.86$119,454-30.88%
2024-04-02SaleChief Operating Officer
1,357
0.0025%
$9.88$13,407-30.88%
2024-02-21SalePresident and CEO
13,033
0.0278%
$7.46$97,226-7.33%
2024-02-21SaleChief Financial Officer
3,764
0.008%
$7.46$28,079-7.33%
2024-02-21SaleChief Operating Officer
3,966
0.0084%
$7.45$29,547-7.33%
2024-02-21SaleChief Scientific Officer
3,365
0.0072%
$7.47$25,137-7.33%
2024-02-20SaleChief Scientific Officer
602
0.0013%
$7.68$4,623-6.21%
2024-01-17SaleChief Operating Officer
2,543
0.0054%
$7.15$18,182+3.42%
2024-01-17SaleChief Scientific Officer
1,266
0.0027%
$7.18$9,090+3.42%
2023-10-03SaleChief Financial Officer
13,567
0.0298%
$6.99$94,833+9.93%
2023-09-15SaleChief Scientific Officer
10,500
0.0245%
$8.16$85,680-2.14%
2023-07-06SaleChief Scientific Officer
5,500
0.0137%
$10.80$59,400-23.12%

Insider Historical Profitability

<0.0001%
NEUROCRINE BIOSCIENCES INC10 percent owner
8575316
15.6983%
$4.2220+7.14%
EcoR1 Capital, LLCdirector
3851507
7.0507%
$4.2213+28.87%
Sanofi
2477941
4.5362%
$4.2210<0.0001%
PAUL STEVEN MPresident and CEO
872351
1.597%
$4.2210<0.0001%
GERAGHTY JAMES Adirector
76588
0.1402%
$4.2220<0.0001%

VYGR Institutional Investors: Active Positions

Increased Positions70+52.24%2M+7.11%
Decreased Positions54-40.3%3M-8.35%
New Positions23New465,537New
Sold Out Positions18Sold Out850,559Sold Out
Total Postitions150+11.94%35M-1.24%

VYGR Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Armistice Capital, Llc$22,825.009.81%5.4M+196,000+3.77%2024-12-31
Blackrock, Inc.$22,659.009.74%5.36M-73,641-1.36%2024-12-31
Ecor1 Capital, Llc$16,571.007.12%3.92M00%2024-12-31
Vanguard Group Inc$13,601.005.85%3.22M+29,014+0.91%2024-12-31
Farallon Capital Management Llc$10,874.004.67%2.57M+278,700+12.16%2024-12-31
Dimensional Fund Advisors Lp$5,840.002.51%1.38M+275,571+24.94%2024-12-31
Vestal Point Capital, Lp$5,203.002.24%1.23M+740,000+151.02%2024-12-31
Geode Capital Management, Llc$4,586.001.97%1.08M+4,729+0.44%2024-12-31
Erste Asset Management Gmbh$4,477.001.92%1.06M00%2024-12-31
State Street Corp$3,811.001.64%900,932+8,189+0.92%2024-12-31

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.